Intensity-modulated Radiation Therapy Combined With Cisplatin or Nedaplatin Chemotherapy in Nasopharyngeal Carcinoma

Phase 2

• Conditions: Nasopharyngeal Carcinoma
• Interventions: Drug: Cisplatin; Drug: Nedaplatin

• Registration Number: NCT01265147
• Lead Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Brief Summary

This phase II trial is studying cisplatin or nedaplatin combine with IMRT to evaluate which one is better efficacy and security in nasopharyngeal carcinoma.

Detailed Description

Not available

Study Timeline

• Status Verified: 2010-11
• Study First Submitted: 2010-12-03
• Study First Submitted QC: 2010-12-22
• Study First Posted: 2010-12-23
• Study Start: 2011-01
• Last Update Submitted: 2011-01-19
• Last Update Posted: 2011-01-20
• Primary Completion: 2012-12
• Study Completion: 2017-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Age≥18,T1-2aN1-3;T2-4NxNPC,VEGFR+,++,KPS>70,Life expectancy≥6 months, No uncontrolled hypertension,cardiac failure,diabetes,lunacy

Read More

Exclusion Criteria

Distant metastasis, recurrent disease

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Cisplatin	Cisplatin	cisplatin combine with IMRT
Nedaplatin	Nedaplatin	Nedaplatin combine with IMRT

Primary Outcome Measures

Name	Time	Method
locoregionally control rate	3 months	3 months after treatment

Secondary Outcome Measures

Name	Time	Method
Survival	1,3,5 years	1 year Progress Free Survival,Disease Free Survival,3 years and 5 years Over All Survival,Safety

Trial Locations

Locations (1)

Daping Hospital; 🇨🇳 Chong Qing, China